United Capital Financial Advisers LLC Grows Stock Position in Icon Plc (NASDAQ:ICLR)
United Capital Financial Advisers LLC raised its holdings in Icon Plc (NASDAQ:ICLR) by 7.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 71,409 shares of the medical research company’s stock after buying an additional 4,863 shares during the quarter. United Capital Financial Advisers LLC owned about 0.13% of Icon worth $10,995,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. HighPoint Advisor Group LLC purchased a new stake in Icon in the first quarter valued at about $218,000. Xact Kapitalforvaltning AB purchased a new stake in Icon in the first quarter valued at about $601,000. Trexquant Investment LP purchased a new stake in Icon in the first quarter valued at about $1,308,000. WCM Investment Management LLC raised its stake in Icon by 2.2% in the second quarter. WCM Investment Management LLC now owns 3,391,296 shares of the medical research company’s stock valued at $522,158,000 after buying an additional 73,167 shares during the last quarter. Finally, Harbour Capital Advisors LLC raised its stake in Icon by 16.5% in the second quarter. Harbour Capital Advisors LLC now owns 3,007 shares of the medical research company’s stock valued at $463,000 after buying an additional 425 shares during the last quarter. Institutional investors own 83.54% of the company’s stock.
ICLR has been the subject of a number of research analyst reports. Mizuho increased their price target on Icon from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. ValuEngine cut Icon from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research cut Icon from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. UBS Group upgraded Icon from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $135.00 to $171.00 in a research note on Friday, July 26th. Finally, BidaskClub cut Icon from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $167.00.
Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.01. Icon had a return on equity of 25.02% and a net margin of 13.05%. The firm had revenue of $695.14 million during the quarter, compared to analysts’ expectations of $693.56 million. During the same period last year, the business posted $1.51 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Icon Plc will post 6.88 earnings per share for the current year.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading: What does a market perform rating mean?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.